...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tumori. >Temozolomide and radiotherapy as first-line treatment of high-grade gliomas.
【24h】

Temozolomide and radiotherapy as first-line treatment of high-grade gliomas.

机译：替莫唑胺和放射疗法作为高级神经胶质瘤的一线治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIMS AND BACKGROUND: Temozolomide, a novel alkylating agent, has shown promising results in the treatment of patients with high-grade gliomas, when used as single agent as well as in combination with radiation therapy. MATERIALS AND METHODS: In this report we retrospectively reviewed the clinical outcome of 128 consecutive patients with a diagnosis of high-grade gliomas referred to our Institutions from April 1994 to November 2001. The first 64 patients were treated with radiotherapy alone and the other 64 with a combination of radiotherapy and temozolomide (31 with radiotherapy and adjuvant temozolomide and 33 with radiotherapy and concomitant temozolomide followed by adjuvant temozolomide). RESULTS: Grade 3 hematological toxicity was scored in 9% of 64 patients treated with radiotherapy and temozolomide. No grade 4 hematological toxicity was reported, and the other acute side effects observed were mild or easily controlled with medications. Age, histology and administration of temozolomide were statistically significant prognostic factors associated with better 2-year overall survival. In contrast, we did not observe a significant difference in overall survival between adjuvant and concomitant/adjuvant temozolomide administration. CONCLUSIONS: We report the favorable results of a schedule combining radiotherapy and temozolomide in the treatment of patients with high-grade gliomas. The literature data and above all the findings of the phase III EORTC-NCIC 26981 trial suggest that actually the schedule can be used routinely in clinical practice. Further clinical studies, using temozolomide in combination with other agents, are required.
机译：目的和背景：替莫唑胺，一种新型的烷基化剂，当用作单一药物以及与放射疗法结合使用时，在治疗高级神经胶质瘤患者中显示出令人鼓舞的结果。材料与方法：在本报告中，我们回顾性地回顾了1994年4月至2001年11月间转诊给我们机构的128例诊断为高度神经胶质瘤的连续患者的临床结局。前64例患者仅接受放射治疗，其余64例接受放射治疗。放疗和替莫唑胺联合治疗（31例联合放疗和替莫唑胺联合放疗，33例联合放疗和替莫唑胺联合放疗，再联合替莫唑胺联合治疗）。结果：在接受放疗和替莫唑胺治疗的64例患者中，有9％达到了3级血液学毒性评分。没有4级血液学毒性的报道，观察到的其他急性副作用是轻度的或易于用药物控制的。替莫唑胺的年龄，组织学和给药是统计学上与2年总生存期延长相关的重要预后因素。相比之下，我们未观察到佐剂和替莫唑胺同时/佐剂的总生存率有显着差异。结论：我们报告了放疗联合替莫唑胺方案治疗高级别胶质瘤的良好效果。文献数据以及最重要的III期EORTC-NCIC 26981试验结果表明，该时间表实际上可以在临床实践中常规使用。需要将替莫唑胺与其他药物联合使用进行进一步的临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号